AlphAIAlphAI — Financial news for AI agents
StockDelisted · Sep 2026NASDAQ · US · USDHealthcare · BIOTECHNOLOGY

$KTTAW

Pasithea Therapeutics Corp.

Price · $KTTAWvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $KTTAW in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $KTTAW in the last 30 days.

See all $KTTAW insider activity →
Top stories · $KTTAWMore →
SEP 8·BenzingaMed

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.

AUG 29·Benzinga

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

MIAMI, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. KTTA ( "Pasithea" or the "Company" ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management's live presentation at the ...

KTTAW sentiment & insider activity

What's driving KTTAW

  • Potential minor positive impact on warrants due to overall company progress, but less pronounced than on common shares.

    Benzinga · Sep 8, 2025

  • Given the low relevance score, KTTAW is unlikely to be significantly affected by the conference update unless KTTA's stock exhibits substantial volatility.

    Benzinga · Aug 29, 2025

  • The issuance of warrants could lead to dilution if exercised, potentially exerting downward pressure on stock price; however, it also signals investor confidence.

    Benzinga · May 7, 2025

AlphAI scores every news story that mentions KTTAW with an AI model for sentiment and relevance, and aggregates insider trades from Pasithea Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $KTTAW

Score
SEP 8$KTTAMedBenzinga

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.

3 min read
AUG 29$KTTAMedBenzinga

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

MIAMI, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. KTTA ( "Pasithea" or the "Company" ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management's live presentation at the ...

2 min read